BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

OBI-1: Interim Phase III data

Interim data from 3 patients with serious bleeding episodes that were not controlled with NovoSeven or Feiba VH in the open-label, Phase III Accur8 Auto-antibody trial showed that IV OBI-1 stopped all serious bleeding episodes at 24 hours, which is the trial's primary endpoint. The...

Read the full 225 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >